The Critical Role RTs Play in Asthma Education - Scorecard - MDSpire

The Critical Role RTs Play in Asthma Education

  • By

  • RC Central Editorial Team

  • May 12, 2026

  • 0 min

Share

Clinical Scorecard: The Essential Contribution of Respiratory Therapists in Asthma Education

At a Glance

CategoryDetail
ConditionAsthma
Key MechanismsChronic disease characterized by long-term airway inflammation, swelling, and mucus production.
Target PopulationApproximately 26.8 million people (8% of the U.S. population) living with asthma.
Care SettingEmergency rooms, schools, and outpatient settings.

Key Highlights

  • Asthma leads to 1 million emergency room visits annually.
  • Over 10 million school days are missed each year due to asthma.
  • Approximately 10 people die daily from asthma-related complications.

Guideline-Based Recommendations

Diagnosis

  • Recognize symptoms of asthma and perform spirometry for confirmation.

Management

  • Implement asthma education programs led by respiratory therapists.

Monitoring & Follow-up

  • Regular follow-ups to assess asthma control and medication adherence.

Risks

  • Increased risk of complications and mortality without proper management.

Patient & Prescribing Data

Individuals diagnosed with asthma, including children and adults.

Education and management strategies are critical for reducing asthma attacks and improving quality of life.

Clinical Best Practices

  • Utilize respiratory therapists for patient education and management.
  • Encourage the use of asthma action plans.
  • Promote awareness of environmental triggers and avoidance strategies.

References

Original Source(s)

The Critical Role RTs Play in Asthma Education

  • by RC Central Editorial Team

  • May 12, 2026

Related Content

Association Between Short-term Exposure to Atmospheric Black Carbon and Acute Exacerbations of Childhood Asthma

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.

FDA Expands Afrezza to Pediatric Diabetes

The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.